Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress

Fan Wang, Lin Liu, Yu Tong, Linfeng Li, Yanfeng Liu & Wei-Qiang Gao
Prostate cancer (PCa) is the second commonly diagnosed malignancy in men over the world. Although androgen deprivation therapy for advanced PCa patients has significantly improved their survival, the majority of these patients eventually develop castration-resistant prostate cancer (CRPC). Proscillaridin A (Pro A), a cardiac glycoside that is clinically used to treat various heart failure diseases, has been reported to have anticancer activity in several cancers. However, whether Pro A exerts an inhibitory effect on PCa...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.